MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Johnson and Johnson

Отворен

СекторЗдравеопазване

153.9 -0.43

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

152.41

Максимум

155.08

Ключови измерители

By Trading Economics

Приходи

3.4B

Продажби

20M

23B

P/E

Средно за сектора

17.455

57.333

EPS

2.77

Дивидентна доходност

3.3

Марж на печалбата

15.235

Служители

138,100

EBITDA

652M

5.9B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+9.18% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.30%

2.63%

Следващи печалби

16.07.2025 г.

Следваща дата на дивидент

10.06.2025 г.

Следваща дата на екс-дивидент

27.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

11B

378B

Предишно отваряне

154.33

Предишно затваряне

153.9

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Johnson and Johnson Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.04.2025 г., 15:12 ч. UTC

Печалби

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15.04.2025 г., 10:35 ч. UTC

Топ новини
Печалби

J&J Increases Outlook After Beating 1Q Expectations

18.04.2025 г., 11:00 ч. UTC

Топ новини

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17.04.2025 г., 20:34 ч. UTC

Печалби

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17.04.2025 г., 18:24 ч. UTC

Печалби

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15.04.2025 г., 19:06 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15.04.2025 г., 18:52 ч. UTC

Пазарно говорене
Печалби

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15.04.2025 г., 14:54 ч. UTC

Печалби

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15.04.2025 г., 13:19 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15.04.2025 г., 11:52 ч. UTC

Печалби

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15.04.2025 г., 11:14 ч. UTC

Печалби

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15.04.2025 г., 10:51 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15.04.2025 г., 10:37 ч. UTC

Топ новини
Печалби

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q Sales $21.89B >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q Orthopaedics Sales $2.24B >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: MedTech 1Q Operational Sales Growth Driven Primarily by Abiomed and Wound Closure Products, Partially Offset by Spine, Sports & Other >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson Still Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson: Innovative Medicine 1Q Sales Growth Driven in Part by Higher Sales of Darzalex and Spravato, Partially Offset by Falling Sales of Stelara >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q U.S. Sales $12.31B >JNJ

15.04.2025 г., 10:20 ч. UTC

Печалби

Johnson & Johnson 1Q EPS $4.54 >JNJ

Сравнение с други в отрасъла

Ценова промяна

Johnson and Johnson Прогноза

Ценова цел

By TipRanks

9.18% нагоре

12-месечна прогноза

Среден 169.15 USD  9.18%

Висок 185 USD

Нисък 159 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Johnson and Johnson през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

14 ratings

7

Купи

7

Задържане

0

Продай

Техническа оценка

By Trading Central

154.36 / 157.47Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.